HIV Negative and HIV Prevention

HPTN 077 - A Phase IIa study to evaluate the safety, tolerability, and pharmacokinetics of the investigational injectable HIV integrase inhibitor, GSK1265744, in HIV-uninfected Men and Women

  • Population: HIV-uninfected men and women at low to minimal risk for acquiring HIV infection, ages 18 to 65
  • Medication: Investigational injectable HIV integrase inhibitor, GSK1265744 vs placebo
  • Duration: 1.5 years
  • Contact: Becky Straub, RN (919) 843-9975 or Miriam Chicurel-Bayard, RN (919) 843-9922

Status: On-going 

CID 0702 - Apheresis procedures to obtain leukocytes from HIV negative subjects

  • Question: Samples used as negative control for exploring new methods of activating resting HIV infected cells in laboratory
  • Population: must be HIV negative and > 18 years of age
  • Duration: up to 3 years
  • Contact: Amanda Crooks 919-843-9564

Status: On-going / Recruiting

HVTN 703/HPTN 085: A Phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection

  • Question: To evaluate the safety and tolerability of VRC01 monoclonal antibody (mAb) administered through IV infusion; determine if the VRC01 mAb prevents HIV-1 infection; and to estimate the level of efficacy
  • Population: HIV-uninfected 18 to 50 year old men and transgender individuals who have sex with men
  • Medication: VRC01 human monoclonal antibody (mAb)
  • Duration: Approximately 22 months with monthly visits
  • Contact: Chris Evans, ANP-BC 919-843-8759 or Alex Delaney, 919-966-8353

Status: On-going / Recruiting